หน้าแรก
ค้นหา
At ASCO 2019, Dr. Hope Rugo presents on results of the SOPHIA breast cancer study
At #ASCO19, Dr. Hope Rugo talks about the SOPHIA Trial in HER2-Positive Metastatic Breast Cancer.
แสดงข้อมูลเพิ่มเติม 1
At ASCO 2019, Dr. Hope Rugo presents on results of the SOPHIA breast cancer study
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior ant...
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
Hope Rugo, MD: Chemotherapy Agents and Breast Cancer Treatment
Breast cancer highlights from ASCO 2019
Breast Cancer: The Next Wave By Dr. Hope Rugo
Message from Dr Hope Rugo on COVID 19 and Cancer Patients
Hope Rugo, MD: Advances and Challenges In the Treatment of Metastatic Breast Cancer
Rugo: De-escalating Systemic Therapy for Breast Cancer
Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer
INspired | Beyond the White Coat with Dr. Hope Rugo
Dra. Hope Rugo destaca os principais estudos no tratamento de câncer de mama na ESMO 2018
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials
Dr. Rugo on Pathway Blockade in Breast Cancer
Hope Rugo, Oncologist + Shelley Hwang, Surgeon (v2)
Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer
Dr. Blum on Takeaways from ABC Trials for Breast Cancer
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
Hope S. Rugo: CALGB 40502/NCCTG N063H
Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial